Search

Novavax Inc

Slēgts

SektorsVeselības aprūpe

9.43 6.43

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

8.26

Max

8.97

Galvenie mērījumi

By Trading Economics

Ienākumi

-44M

-53M

Pārdošana

-83M

57M

P/E

Sektora vidējais

3.112

57.371

EPS

-0.32

Peļņas marža

-94.16

Darbinieki

749

EBITDA

-39M

-40M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+48.21% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 5. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

113M

1.3B

Iepriekšējā atvēršanas cena

3

Iepriekšējā slēgšanas cena

9.43

Ziņu noskaņojums

By Acuity

13%

87%

17 / 340 Rangs Healthcare

Novavax Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. aug. 20:04 UTC

Novavax shares are lower today, reflecting broader market trends, with no specific company news identified. The stock remains above its 20-day moving average.

2026. g. 21. aug. 23:31 UTC

Novavax Inc. shares declined in after-market trading, moving within a narrow range since Friday's close. The stock remains above its 20-day moving average.

2026. g. 20. aug. 19:02 UTC

Macro Event

Novavax shares are trading lower amid negative jobless claims data, reflecting broader market fluctuations and a significant decline since Wednesday's close.

2026. g. 19. aug. 23:51 UTC

Novavax Inc. shares are lower in after-market hours amid broader declines in biotechnology stocks, despite an earlier session peak above Wednesday's close.

2026. g. 17. aug. 19:36 UTC

Novavax Inc is trading higher, reaching a session peak earlier today. The stock remains at the upper end of its one-month trading range.

2026. g. 14. aug. 23:26 UTC

Novavax Inc. shares are trading roughly flat in after-market hours, remaining above the 20-day moving average and near the upper end of the one-month range.

2026. g. 13. aug. 19:16 UTC

Novavax Inc. shares are higher today, maintaining strength above the 20-day moving average despite rising initial jobless claims reported by the Labor Department.

2026. g. 12. aug. 23:31 UTC

Novavax Inc. shares are lower in after-market trading, reflecting a weaker trend despite earlier gains. The stock remains above its 20-day moving average.

2026. g. 11. aug. 23:51 UTC

Novavax Inc. shares are higher in after-market trading, maintaining a position above the 20-day moving average within its one-month trading range.

2026. g. 10. aug. 23:46 UTC

Novavax Inc. shares are lower in after-market trading, showing some volatility since Monday's close and remaining within the middle of their one-month trading range.

2026. g. 7. aug. 19:36 UTC

News

Novavax Inc shares are higher today, supported by $57 million in second-quarter revenue and ongoing discussions with Sanofi on a COVID-19/influenza vaccine.

2026. g. 6. aug. 23:01 UTC

News

Novavax Inc expects 2026 revenue of $235 million to $275 million. Shares are trading higher in after-market hours following the earnings call.

2026. g. 5. aug. 23:01 UTC

Novavax shares are higher in after-market trading, though they remain below the 20-day moving average amid weaker-than-expected U.S. job growth data.

2026. g. 4. aug. 23:36 UTC

Novavax Inc. shares are higher in after-market trading, despite remaining below their 20-day moving average. Broader market sentiment may support this upward movement.

2026. g. 3. aug. 23:46 UTC

News

Novavax Inc is advancing in after-market trading as it shifts focus to licensing its Matrix-M adjuvant, attracting positive retail investor sentiment ahead of earnings.

2026. g. 31. jūl. 19:16 UTC

Novavax Inc. shares are lower today, reflecting a decline from Thursday's close amid rising bond yields and crude oil prices contributing to inflation concerns.

2026. g. 30. jūl. 22:01 UTC

Novavax Inc. shares advanced in after-market trading, rebounding from earlier session lows, though they remain below the 20-day moving average.

2026. g. 29. jūl. 23:06 UTC

Novavax Inc. shares are higher in after-market trading, gaining slightly since Wednesday's close, despite broader market weakness and significant declines over the past month.

2026. g. 28. jūl. 16:06 UTC

Novavax Inc. shares are lower today, reflecting broader market declines amid investor caution ahead of earnings and the Federal Reserve's interest rate decision.

2026. g. 27. jūl. 14:02 UTC

Novavax Inc shares are higher in pre-market trading, rising to $7.73. This increase occurs amid three consecutive lower session closes and mixed economic data.

2026. g. 24. jūl. 18:46 UTC

Novavax Inc. shares are lower today, continuing a trend of declines following three consecutive sessions of lower closes and trading below the 20-day moving average.

2026. g. 23. jūl. 09:01 UTC

Novavax Inc shares are higher in pre-market trading, reflecting upward momentum since Wednesday. Broader market sentiment remains positive amid rising Asian equity indices.

2026. g. 22. jūl. 23:11 UTC

Novavax Inc. shares are higher in after-market hours, driven by strength in biotechnology stocks. The company remains below its 20-day moving average.

2026. g. 21. jūl. 22:46 UTC

Novavax Inc. shares declined in after-market trading, remaining below their 20-day moving average despite a broader market rebound in the tech sector.

2026. g. 20. jūl. 23:46 UTC

Novavax Inc. shares traded roughly flat after-market with no specific news identified. The stock remains significantly below its 20-day moving average.

Salīdzinājums

Cenas izmaiņa

Novavax Inc Prognoze

Cenas mērķis

By TipRanks

48.21% augšup

Prognoze 12 mēnešiem

Vidējais 13.25 USD  48.21%

Augstākais 19 USD

Zemākais 7 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Novavax Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

4 ratings

2

Pirkt

1

Turēt

1

Pārdot

Noskaņojums

By Acuity

17 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat